A Decade of Transformation in China's Innovative Drug Industry: The Journey from Follower to Leader
Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro
March 14, 2025
by Kevin
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights!
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
January 23, 2025
by Sophia
Selection of Commercial Models for Innovative Drugs
Marketing is the crucial stage in the life cycle of a pharmaceutical product, directly determining the success of its development. Large pharmaceutical companies typically possess a robust sales system, giving them a unique advantage in terms of first-mov
May 21, 2024
by WND
An Overview to 2023 Pharmaceutical Industry by PharmaSources Experts
20 Selected Articles by PharmaSources Experts in 2023
March 7, 2024
by PharmaSources
The Narrative of Pharmaceuticals Bestowed with Endorsement and Later Reclaimed by Oblivion by the FDA
This document endeavors to compile and elucidate data pertaining to instances where the U.S. FDA, in recent years, has rescinded market approval for pharmaceuticals previously sanctioned.
March 6, 2024
by zhulikou431
Pharma Sources Insight April 2023: Innovative Drugs Going Abroad
A look into the innovative drugs R&D and
emerging market.
April 18, 2023
by Pharma Sources Insight
Summary and Brief Analysis of New Drugs Approved by NMPA in 2021
With the revision and promulgation of the Drug Administration Law in 2019, Chinese drug review and approval system has been strengthened and improved.
March 29, 2022
by PharmaSources/zhulikou431
Similarities and Differences of Medical Insurance System Development among Foreign Countries and China
Recently, the news of national medical insurance negotiations has constantly touched the heartstrings of pharmaceutical people.
January 4, 2022
by PharmaSources/Big Cat of Medical Field
Innovative Drugs of Chinese Pharmaceutical Companies have Obtained Overseas Authorization and Developed Rapidly
In March 2007, Chipscreen licensed the global development rights of chidamide, a product under research, to HUYA of the United States at a price of USD 28 million.
December 17, 2021
by PharmaSources/Xiaoyaowan
ADC vs PDC-- Status Quo of the R&D of ADC-PDC Drug in China and the World
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
November 15, 2021
by PharmaSources/zhulikou431
Analysis on the Layout of Innovative Drugs in China and Globally
Recently, there is a saying in the pharmaceutical industry: not all innovative drugs have a future. This saying reminds me of the lyrics - wild lilies also have spring.
October 27, 2021
by PharmaSources/Zhulikou431
With Anlotinib Sold over RMB4 Billion in 2020, Which will be the Next Blockbuster of Sino Biopharmaceutical?
Sino Biopharmaceutical has recently released its 2020 annual results, with total revenue of RMB23.647 billion, down 2.4% year on year, net profit attributable to the parent of RMB2.771 billion, up 0.3% year on year
May 31, 2021
by PharmaSources/Caicai